Login to Your Account

TTNP Plummets 42%

Committee to Scrutinize Titan's Implantable Buprenorphine

By Catherine Shaffer
Staff Writer

Wednesday, March 20, 2013
Briefing documents released ahead of a scheduled meeting March 21 of the Psychopharmacologic Drugs Advisory Committee sent shares of Titan Pharmaceuticals Inc. plummeting 41.7 percent Tuesday.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription